MORRISTOWN, N.J., March 9, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a global integrated pharmaceutical company, announced today that David A. Buchen has been promoted to Executive Vice President, General Counsel and Secretary, and R. Todd Joyce has been promoted to Executive Vice President, Chief Financial Officer. Both continue to report to Paul M. Bisaro, President and Chief Executive Officer.
"These promotions not only recognize the substantial individual contributions David and Todd have made to Watson's ongoing success, but also the significant achievements made by both in building the teams that support our Company's global growth," said Bisaro. "With the increasing complexity of our global portfolio – generics, brands and biologics – our international legal team has been increasingly called upon under David's leadership to support a broad array of competitive, compliance and intellectual property legal activities. Todd and his team have ensured the seamless integration of our global finance operations following the Arrow acquisition, and demonstrated the leadership required to manage our global finances which have allowed us to deliver on our financial commitments while maintaining our capacity for continued growth and expansion. Both promotions are well deserved and reflect the importance of these functions and the role of these two leaders in our success."
Mr. Joyce was appointed Senior Vice President, Chief Financial Officer of Watson in October 2009. He joined Watson in 1997 as Corporate Controller and was named Vice President, Corporate Controller and Treasurer in 2001. During the periods October 2006 to November 2007 and from July 2009 until October 2009, Mr. Joyce served as interim Principal Financial Officer.
Prior to joining Watson, Mr. Joyce served as Vice President of Tax from 1992 to 1996 and as Vice President of Tax and Finance from 1996 until 1997 at ICN Pharmaceuticals. Prior to ICN Pharmaceuticals, Mr. Joyce served as a Certified Public Accountant with Coopers & Lybrand and Price Waterhouse. He received a B.S. in Business Administration from the University of North Carolina at Chapel Hill in 1983 and a M.S. in Taxation from Golden State University in 1992.
Mr. Buchen has served as Senior Vice President, General Counsel and Secretary since November 2002. From November 1998 to November 2002, he served in a number of increasingly responsible positions. Prior to joining Watson, Mr. Buchen was Corporate Counsel at Bausch & Lomb Surgical (formerly Chiron Vision Corporation) from November 1995 until November 1998 and was an attorney with the law firm of Fulbright & Jaworski, LLP. Mr. Buchen received a B.A. in Philosophy from the University of California, Berkeley in 1985, and a Juris Doctor with honors from George Washington University Law School in 1989.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a global integrated pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.
SOURCE Watson Pharmaceuticals, Inc.